Erik Upeslacis

480 citations
7 papers · 270 indexed · h-index 5
Topics
HER2/EGFR in Cancer Research (3 papers)Protein Kinase Regulation and GTPase Signaling (2 papers)Cancer-related Molecular Pathways (2 papers)
Partner nations
United StatesCanada

In The Last Decade

Erik Upeslacis

7 papers receiving 258 citations

Peers

Erik Upeslacis
Comparison fields: 5 of 43
  • Molecular Biology 150
  • Organic Chemistry 122
  • Oncology 84
  • Computational Theory and Mathematics 31
  • Pulmonary and Respiratory Medicine 26
Replace Atsuo Baba with:
Atsuo Baba Japan
Anthony S. Prokopowicz United States
Allison M. Roberts United States
John P. Wolak United States
Pondy Murugappan Ramanujulu Singapore
Carolyn A. Weigelt United States
Brian G. Hartl New Zealand
Weifang Shan United States
Todd Vo United States
Carole Pissot‐Soldermann Switzerland
Erik Upeslacis relative to Atsuo Baba Japan Atsuo Baba's profile →
Citations per field
00.5×1.7×
Atsuo Baba · 1×
Citations per year

Countries citing papers authored by Erik Upeslacis

Since Specialization
Citations

This map shows the geographic impact of Erik Upeslacis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Upeslacis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Upeslacis more than expected).

Fields of papers citing papers by Erik Upeslacis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Upeslacis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Upeslacis. The network helps show where Erik Upeslacis may publish in the future.

Co-authorship network of co-authors of Erik Upeslacis

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Upeslacis. A scholar is included among the top collaborators of Erik Upeslacis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Upeslacis. Erik Upeslacis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
#WorkIndexed citations
1 13
2 6
3 3
4 25
5 39
6 1
7 183

About Erik Upeslacis

Erik Upeslacis is a scholar working on Oncology, Immunology and Allergy and Pharmacology, having authored 7 papers that have together received 270 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (3 papers), Protein Kinase Regulation and GTPase Signaling (2 papers) and Cancer-related Molecular Pathways (2 papers). The work is most often cited by research in Organic Chemistry (122 citations), Oncology (84 citations) and Toxicology (10 citations). Erik Upeslacis has collaborated with scholars based in United States and Canada. Frequent co-authors include M. Brawner Floyd, Ramaswamy Nilakantan, Bernard D. Johnson, Ru Shen, Allan Wissner, Biqi Wu, Fei Ye, Nellie Mamuya, Dan M. Berger and Hwei‐Ru Tsou. Their work appears in journals such as Cancer Research, Oncogene and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026